[The treatment of muscular dystrophy with the nucleoside-nucleotide mixture Laevadosine]. 1967

H Radu, and K Stenzel, and S Migea, and L Bordeianu

UI MeSH Term Description Entries
D009136 Muscular Dystrophies A heterogeneous group of inherited MYOPATHIES, characterized by wasting and weakness of the SKELETAL MUSCLE. They are categorized by the sites of MUSCLE WEAKNESS; AGE OF ONSET; and INHERITANCE PATTERNS. Muscular Dystrophy,Myodystrophica,Myodystrophy,Dystrophies, Muscular,Dystrophy, Muscular,Myodystrophicas,Myodystrophies
D009705 Nucleosides Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleoside,Nucleoside Analog,Nucleoside Analogs,Analog, Nucleoside,Analogs, Nucleoside
D009711 Nucleotides The monomeric units from which DNA or RNA polymers are constructed. They consist of a purine or pyrimidine base, a pentose sugar, and a phosphate group. (From King & Stansfield, A Dictionary of Genetics, 4th ed) Nucleotide
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003402 Creatine Kinase A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins. Creatine Phosphokinase,ADP Phosphocreatine Phosphotransferase,ATP Creatine Phosphotransferase,Macro-Creatine Kinase,Creatine Phosphotransferase, ATP,Kinase, Creatine,Macro Creatine Kinase,Phosphocreatine Phosphotransferase, ADP,Phosphokinase, Creatine,Phosphotransferase, ADP Phosphocreatine,Phosphotransferase, ATP Creatine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Radu, and K Stenzel, and S Migea, and L Bordeianu
May 2001, Nihon rinsho. Japanese journal of clinical medicine,
H Radu, and K Stenzel, and S Migea, and L Bordeianu
November 1991, Nihon rinsho. Japanese journal of clinical medicine,
H Radu, and K Stenzel, and S Migea, and L Bordeianu
September 1971, Wiener medizinische Wochenschrift (1946),
H Radu, and K Stenzel, and S Migea, and L Bordeianu
June 1967, Arzneimittel-Forschung,
H Radu, and K Stenzel, and S Migea, and L Bordeianu
October 1969, Journal of the Indian Medical Association,
H Radu, and K Stenzel, and S Migea, and L Bordeianu
June 1969, The Medical journal of Australia,
H Radu, and K Stenzel, and S Migea, and L Bordeianu
October 1969, The Medical journal of Australia,
H Radu, and K Stenzel, and S Migea, and L Bordeianu
December 2015, Nihon rinsho. Japanese journal of clinical medicine,
H Radu, and K Stenzel, and S Migea, and L Bordeianu
March 1966, Modern treatment,
H Radu, and K Stenzel, and S Migea, and L Bordeianu
May 1964, Indian journal of pediatrics,
Copied contents to your clipboard!